Document is current

Article History

Received: 5 September 2025

Accepted: 1 November 2025

First Online: 29 November 2025

Declarations

:

: The study was conducted in alignment with the Declaration of Helsinki, and approved by the institutional review board of the Medical University of Vienna (1079/2023).

: Written informed consent was obtained from all participants prior to their inclusion in the registry for baseline and follow-up assessments.

: All individuals agreed to the publication of this manuscript.

: CPS received consulting and speaker fees from Pfizer. RR received speaker fees and congress support from Akcea Therapeutics, Alnylam Pharmaceuticals, AstraZeneca, Bayer, Pfizer Inc., and Swedish Orphan Biovitrum, as well as research grants from Pfizer Inc. FD received Speaker fees and congress support from Bayer, Novartis, Alnylam, Pfizer, and AOP, as well as research grants from the Austrian Society of Cardiology, Pfizer, Alnylam, and Bayer. CN reports speaker/consulting honoraria from Pfizer, Bayer, Prothena, and Böhringer Ingelheim and research contracts with Pfizer, AstraZeneca, the Austrian Society of Cardiology, the European Association of Cardiovascular Imaging, and the Austrian Science Fund. DK has received support from the German Research Foundation (UMEA Clinician Scientist Academy, FU356/12 − 2, and KE2933/1–1) and reports fees from Pfizer (research funding, speaker), Novartis (speaker), and GE Healthcare (consultant) outside the submitted work. MH has received lecture fees from Siemens Healthineers and GE Healthcare. MH has received consulting fees from Evomics. The remaining authors have nothing to declare.